Please enable Javascript
Muscle Invasive Urothelial Carcinoma
Advertisement
RaDaR Sequencing Test Could Determine Possibility of Surgery for Patients With MIBC
Emily Menendez
Muscle Invasive Urothelial Carcinoma
|
March 23, 2023
The RaDar assay tracks up to 48 tumor-specific variants in cell-free DNA in a cancer patient’s blood plasma.
Read More
RETAIN: Risk-Enabled Therapy After Neoadjuvant Chemo for MIBC
Daniel M. Geynisman, MD
ASCO GU Symposium 2023
|
February 23, 2023
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
View More
HCRN GU 16-257: Neoadjuvant Therapy for Patients With MIBC
Matthew D. Galsky, MD
ASCO GU Symposium 2023
|
February 17, 2023
Matthew Galsky, MD, contextualizes HCRN GU 16-257 as a potential game-changer for bladder sparing in patients with MIBC.
View More
Intra-arterial Chemotherapy Plus Radiotherapy Versus Cystectomy for Patients With MIBC
Zachary Bessette
ASCO GU Symposium 2023
|
February 17, 2023
IAC-RT may be a useful and tolerable treatment option for patients with MIBC who are unfit for radical cystectomy.
Read More
Does Fragmented Care Result in Worse Outcomes for Patients With Bladder Cancer?
Emily Menendez
Muscle Invasive Urothelial Carcinoma
|
January 23, 2023
Researchers examined the impact of care fragmentation on patients receiving neoadjuvant chemotherapy and radical cystectomy.
Read More
Deep Learning Radiomics Signature Accurately Predicts Muscle-Invasive Status of Bladder Cancer
Zachary Bessette
Muscle Invasive Urothelial Carcinoma
|
December 6, 2022
DLRS-based MLP was clinical useful in distinguishing non-muscle-invasive bladder cancer from muscle-invasive bladder cancer.
Read More
DNA Repair Protein Linked to MIBC-Specific Mortality
Leah Lawrence
Muscle Invasive Urothelial Carcinoma
|
November 28, 2022
MRE11 “has been identified as a candidate predictive biomarker," as higher levels are associated with more ...
Read More
PURE-01 Trial on Muscle-Invasive Urothelial Carcinoma: A 3-Year Update
Emily Menendez
Muscle Invasive Urothelial Carcinoma
|
October 31, 2022
At a 36-month follow-up, the EFS and OS rates were 74.4% and 83.8% in the ITT group, and 92% of patients underwent RC.
Read More
VESPER’s ddMVACx6 Regimen Cost-Effective for Muscle-Invasive Bladder Cancer
Leah Lawrence
Muscle Invasive Urothelial Carcinoma
|
October 31, 2022
ddMVACx6 was demonstrated to improve progression-free survival compared with GCx4 for muscle-invasive disease.
Read More
Study Questioned Benefit of Adjuvant ICI in Localized Muscle-Invasive Urothelial Carcinoma
Leah Lawrence
Muscle Invasive Urothelial Carcinoma
|
October 25, 2022
The data, published in Clinical Genitourinary Cancer, showed a lack of benefit of adjuvant ICIs across multiple subgroups.
Read More
Neoadjuvant Atezolizumab Associated With High DFS in Muscle-Invasive Bladder Cancer
Cecilia Brown
Muscle Invasive Urothelial Carcinoma
|
August 15, 2022
A trial utilized atezolizumab, a monoclonal antibody directed at the PD-L1 protein, in patients with MIBC.
Read More
Development of a MRI-Based Radiomics Nomogram for Prediction of Response of Patients With Muscle-Invasive Bladder Cancer to Neoadjuvant Chemotherapy
GU Oncology Now Editors
Muscle Invasive Urothelial Carcinoma
|
June 1, 2022
...
Read More
Could Concurrent Capecitabine with Hypofractionated Radiotherapy in Elderly Patients with Muscle-Invasive Bladder Cancer be an Option?
GU Oncology Now Editors
Muscle Invasive Urothelial Carcinoma
|
May 29, 2022
...
Read More
Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review
GU Oncology Now Editors
Muscle Invasive Urothelial Carcinoma
|
May 28, 2022
...
Read More
Optimization of Preoperative Lymph Node Staging in Patients with Muscle-Invasive Bladder Cancer Using Radiomics on Computed Tomography
GU Oncology Now Editors
Muscle Invasive Urothelial Carcinoma
|
May 28, 2022
...
Read More
Uroplakin II as a single marker for luminal versus basal molecular subtypes in muscle invasive urothelial carcinoma
GU Oncology Now Editors
Muscle Invasive Urothelial Carcinoma
|
May 25, 2022
...
Read More
Nivolumab After Bladder Cancer Surgery Improves Survival Rates
Emily Menendez
Muscle Invasive Urothelial Carcinoma
|
May 25, 2022
Clinical trial results showed that immunotherapy drug nivolumab helps reduce cancer recurrence in bladder cancer patients.
Read More
Less Is More
GU Oncology Now Editors
Muscle Invasive Urothelial Carcinoma
|
May 24, 2022
...
Read More
Effects of treatments on gender differences in patients with localized muscle-invasive bladder cancer
GU Oncology Now Editors
Muscle Invasive Urothelial Carcinoma
|
May 24, 2022
...
Read More
Establishment of an experimental model of normal dog bladder organoid using a three-dimensional culture method
GU Oncology Now Editors
Muscle Invasive Urothelial Carcinoma
|
May 24, 2022
...
Read More
Load More
Advertisement
Advertisement
Advertisement